• 1
    Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:319.
  • 2
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29:S438.
  • 3
    Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998;40:S215.
  • 4
    Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:4816.
  • 5
    Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:3319.
  • 6
    Bosello O, Armellini F, Zamboni M, Fitchet M. The benefits of modest weight loss in Type II diabetes. Int J Obes Relat Metab Disord 1997;21:S103.
  • 7
    National Institutes of Health. Consensus development conference on diet and exercise in non-insulin-dependent diabetes mellitus. Diabetes Care 1987;10:63944.
  • 8
    Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:171121.
  • 9
    DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281303.
  • 10
    Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care 2005;28:5964.
  • 11
    Garber AJ. Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabetes Obes Metab 2002;4:S512.
  • 12
    Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to Type 2 Diabetes. Diabetes Care 1997;20:174466.
  • 13
    Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:186772.
  • 14
    Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications 2005;19:11322.
  • 15
    American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:91732.
  • 16
    Academy of Managed Care Pharmacy. The AMCP format for formulary submissions. April, 2005, Version 2.1.
  • 17
    Triplitt C, Chiquette E. Exenatide: from the Gila monster to the pharmacy. J Am Pharm Assoc 2006;46:4455.
  • 18
    DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092100.
  • 19
    Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E15561.
  • 20
    Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulphonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:262835.
  • 21
    Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:108391.
  • 22
    BYETTA (exenatide) injection prescribing information. Amylin Pharmaceuticals, Inc. 2007.
  • 23
    Kendall DM, Kim DD, Poon T, et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks. Diabetes 2005;54(Suppl. 1):A45.
  • 24
    Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:43647.
  • 25
    Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:163741.
  • 26
    American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:22625.
  • 27
    Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:S526.
  • 28
    Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S2740.
  • 29
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:97786.
  • 30
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:83753.
  • 31
    Buse JB, Klonoff DC, Nielsen LL, et al. Effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes. Clin Ther 2007;29:13953.
  • 32
    CPI Inflation Calculator. Available from:[Accessed September 1, 2005].
  • 33
    Jonsson B; CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002;45:S512. Epub 2002 May 24.
  • 34
    Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:21730.
  • 35
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996.
  • 36
    Hunink MG, Bult JR, De Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998;18:33746.
  • 37
    American Diabetes Association. Guidelines for computer modelling of diabetes and its complications. Diabetes Care 2004;27:22625.
  • 38
    Mark DB, Simons TA. Fundamentals of economic analysis. Am Heart J 1999;137:S3840.
  • 39
    Wintle M, Bhole D, Mac S, et al. Improvements in cardiovascular risk factors accompanied improved glycaemia and weight reduction in a european population of patients with type 2 diabetes treated with open-label exenatide for 25 y. Diabetic Med 2006;23(Suppl 4):P1538.
  • 40
    Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:17.
  • 41
    Harris MI, Cowie CC, Stern MP. Diabetes in America (2nd ed.). Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 1995. Report no. 95-1468 (NIH publication no. 95-1468).
  • 42
    Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:16149.
  • 43
    Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N9.
  • 44
    Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:34459.
  • 45
    Miller CD, Phillips LS, Tate MK, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000;23:4448.
  • 46
    Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:7548.
  • 47
    Brändle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:23004.
  • 48
    Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:61016.
  • 49
    Benett IJ, Lambert C, Hinds G, Kirton C. Emerging standards for diabetes care from a city-wide primary care audit. Diabet Med 1994;11:48992.
  • 50
    Massing MW, Foley KA, Sueta CA, et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care 2003;26:9917.
  • 51
    McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:71823.
  • 52
    O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:101738.
  • 53
    DRG Guidebook. A Comprehensive Resource to the DRG Classification System (17th ed.). Eden Prairie, MN: St. Anthony Publishing, 2001.
  • 54
    Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003;26:230510.
  • 55
    Fleming T (Ed). Medical Economics Company. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, 2000.
  • 56
    Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:6607.
  • 57
    Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001;27:34751.